FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

Cosman, Felicia; Crittenden, Daria B; Ferrari, Serge; Khan, Aliya; Lane, Nancy E; Lippuner, Kurt; Matsumoto, Toshio; Milmont, Cassandra E; Libanati, Cesar; Grauer, Andreas

doi:10.1002/jbmr.3427

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

Romosozumab is a bone-forming agent with a dual effect of increasing bone formation and decreasing bone resorption. In FRActure study in postmenopausal woMen with ostEoporosis (FRAME), postmenopausal women with osteoporosis received romosozumab 210 mg s.c. or placebo once monthly for 12 months, f…